FDA Counsel.com Understanding Contracts in the Clinical Research Process North Texas Chapter...
-
Upload
bridget-washington -
Category
Documents
-
view
219 -
download
0
Transcript of FDA Counsel.com Understanding Contracts in the Clinical Research Process North Texas Chapter...
FDACounsel.com
Understanding Contracts in the Clinical Research Process
North Texas ChapterAssociation of Clinical Research Professionals
FALL SYMPOSIUM
October 16, 2004
Michael A. Swit, Esq.FDACounsel.com
THE LAW OFFICES OF MICHAEL A. SWIT539 Samuel Ct., Suite 229
Encinitas, CA 92024760-815-4762 ♦ fax: 760-454-2979
FDACounsel.com 2
Subtitle ?
Do you really Understand what you either just
signed or were just asked to sign?Or …
Everything you always wanted to know about study contracts in
90 minutes?
FDACounsel.com 3
What we will go over …
Part I -- Various kinds of contracts encountered in the clinical research context
Part II -- Key contract clauses, with an emphasis on the actual clinical trial agreement: What they do Pros and cons Different views of what’s important –
e.g., site vs. sponsor
FDACounsel.com 4
PART I
FREQUENTLY ENCOUNTEREDCONTRACT TYPES
FDACounsel.com 5
The Various Contracts You May Meet in Your Journey Clinical Trial Agreement Others Types of Contracts:
Confidentiality Agreement Letter of Intent CTA Master Agreement Indemnification Agreement (Letter
of Indemnification – Unilateral) Consulting Agreement Material Transfer Agreement
FDACounsel.com 6
Confidentiality Agreement Confidentiality Agreement (AKA:
Non-disclosure Agreement) (“CDA” or “NDA”)
What is it? An agreement designed to protect proprietary and confidential information from misuse by those who have learned of them.
Circumstance: Prior to entering into CTA or master agreement. Review of information to determine whether to participate in a study.
FDACounsel.com 7
Confidentiality Agreement
Core terms for effective management. determine scope of CDA, definition of what is
confidential and proprietary information, labeling of information, period of confidentiality, end date.
CDA should be merged into, or be superceded by, CTA if a CTA is executed. For academic centers where center is not a party to the CDA, be sure to exclude CDA from CTA – as the terms may be against center policy. Assure people working on the study are bound.
Tips: Validity of CDA if signed personally by Investigator (If investigator is party to CDA – university/entity may not recognize the CDA as binding)
FDACounsel.com 8
Letter of Intent (“LOI”)
What is it? A letter from one party to another acknowledging a willingness and ability to do business.
Core Terms and effective management: confidentiality, indemnification, insurance, payment
Tips and traps. This usually is NOT a “contract” and cannot be
enforced. Be sure to follow up with a contract. Include a term for automatic renewal to avoid
amendments Personally, I don’t like them because, if worded
correctly, still may be binding and, if not binding, may waste a lot of time in negotiating
Circumstance used? Work to be done on a project during contract negotiations. LOI evidences serious intent assume certain obligations/duties until the contract is executed.
FDACounsel.com 9
Master Service Agreements
What is it? A Master Agreement provides the framework of terms and conditions governing specified current and future clinical activities between two parties for a particular period of time. Each project subject to the terms/conditions of Master is set forth in an attachment outlining study specific info.
Circumstance: A sponsor conducts many clinical trials at a particular site. Master agreement with core terms is executed and each study is defined in an attachment to the Master Agreement. Advantage: cuts down on time/expense of negotiating basic contract terms.
FDACounsel.com 10
Master Service Agreements … Core terms and effective management: same as
the counterpart CTA, Services Agreement. Specific end date.
Attachment: also known as “task order”, “work order”, “addendum”, “letter of agreement”, “clinical trial request form”
Includes study specific info, exceptions to master agreement terms, protocol, budget, informed consent
Tips: Maintain local files of Master Agreements for
reference. Provide copy of master with each task order executed to the investigator.
track end dates/automatic renewals for renegotiation or termination.
Be very careful with Task Order negotiation that it does not modify a key term of the MSA
FDACounsel.com 11
Letter of Indemnification What is it? A letter from one party to another
outlining the liability and indemnity obligations of the parties. Liability v. Indemnity
Liability – condition of being responsible for a possible or actual loss
Indemnity- a contractual right under which loss is shifted from a party passively at fault to the party that is primarily or actively responsible
Example – Physician at a medical center is carrying out clinical study for a pharmaceutical sponsor in accordance with sponsor’s protocol. A research subject is injured. Sponsor is primarily responsible as it is sponsor’s protocol. Therefor, the sponsor agrees to take “responsibility” for any claims made against the investigator. Reimbursement for expenses.
Often is a key clause in a CTA or MSA
FDACounsel.com 12
Letter of Indemnification …
Circumstance: CRO contracts directly with a site – sponsor is a third party beneficiary of the contract, but is not a party to the contract. LOI executed between the sponsor and the site. Actual research site is different from contracting party.
Core terms and effective management: scope of indemnity (limitation on claims), indemnities, subject injury, insurance provision
Tips and Traps: certificates of insurance additional insured status Types of negligence (simple vs. gross) and
intentional wrongdoing Public institutions may not legally be able to provide
FDACounsel.com 13
Consulting Agreements What is it? Additional activities beyond
normal scope of employment, and based in the appropriate discipline for which the individual receives additional compensation during the contract year
Circumstance: Investigator is assisting in the design of a study and/or study protocol, operational expertise or press/network value.
Core terms and effective management: scope of services, IP terms, term of agreement with specific end dates. For academia, right to termination (what if PI leaves?)
FDACounsel.com 14
Consulting Agreements … Tips and traps:
Academic consultants: if consultant is a university faculty member, look to
university policy or guidelines prior to execution. University/academic center often needs to be involved
if one of the following apply: conduct of research (not merely advisory), services performed as part of university commitment, use of university resources
Conflicts of interest -- clinical research consulting agreements, especially involving academia, may create a conflict of interest.
Be sure this conflict is managed appropriately.
FDACounsel.com 15
Material Transfers Agreement (“MTA”) What is it? Agreement controlling the transfer
– often without charge -- of material such as study drug, devices, biologics (cell lines, DNA/RNA, human tissue) from one party to another.
MTA defines the legal rights of the entity donating the material as well as the recipient with respect to the material and any derivatives.
Circumstance: Investigator-initiated trial where party is supplying drug/device and no funding. Also seen in collaborative settings (two academic centers)
FDACounsel.com 16
Material Transfer Agreements … Core terms: rights and restrictions to
use of material, patent and licensing terms,
Effective management: MTA’s sometimes executed in conjunction with another agreement – e.g., MTA for transfer of drug and CTA for study. Assure documents are consistent.
Tips and Traps: IP counsel and Technology Transfer officers are good resources for these agreements.
FDACounsel.com 17
PART II
FREQUENTLY-ENCOUNTERED CONTRACT CLAUSES
FDACounsel.com 18
Parties
Who are the parties to the Agreement?
Problems encountered: PI as a party to the Agreement
Problem: Some sites will not recognize an agreement signed only by the principal investigator.
Happy medium:
Sponsor: obtain site signatureSite: OK, more control over PI
FDACounsel.com 19
Parties … Problem: Some sites will not allow
investigator to sign as a party to the agreement (do not want PI personally liable) Happy medium: Have PI sign as “read and
understood” or “acknowledged” (remember, PI MUST complete and sign 1572 Form which outlines his obligations in accordance with 21 CFR 312)
Sponsor: not a big issue; PI still owes a fiduciary duty to allSite: insulates PI from contractual liability
FDACounsel.com 20
Parties … Agreement is between CRO and Site/PI
Problem: Sponsor is not a party (but has obligations in the trial – see 21 CFR 312)
Happy medium: Site will want to obtain: Evidence of Sponsor/CRO relationship (may have
executed a letter for sites) Agency letter between Sponsor & CRO Letter of Indemnification -- or better yet Combo letter (agency, indemnification,
insurance, subject injury)Sponsor: should want to ensure control over siteSite: wants to make sure it has remedy vs. Sponsor
FDACounsel.com 21
Scope of Work Assure a clearly defined and
comprehensive scope of work. CTA:
Protocol Specify investigators duties
Services Agreements: Specifications
Problem: if you don’t, costs may jump
FDACounsel.com 22
Debarment Debarment
What is it? Federal Regulations
Debarment – See 21 USC 335(a) and (b) Authorizes FDA to preclude
individuals/corporations form participating in the drug industry in any capacity whatsoever
Results from criminal acts such as falsifying data, bribing FDA officials for preferential treatment
When filing for drug approval, a drug company must submit a signed statement that no debarred person worked on the application (includes consultants/contractors)
$1M fine http://www.fda.gov/ora/compliance_ref/debar/
FDACounsel.com 23
Debarment …
Disqualification - See 21 CFR 312.70 Prevents investigator from receiving
investigational drugs Results from criminal acts such as
falsifying data and other egregious GCP
http://www.fda.gov/ora/compliance_ref/bimo/disqlist.htm
FDACounsel.com 24
Debarment … Problems
Qualifying language –this is a federal law “To the best of knowledge” Happy Medium: Assure due diligence
Check website Contact FDA’s Office of Enforcement for up-to-date
debarment list:12720 Twinbrook ParkwayRockville, MD 20852(301)827-0410fax: (301)[email protected]
Site: Limit scope of debarment/disqualification to those individuals performing work on a specific study.
Institute use of a pre-clinical trial form: PI and any subinvestigator warrants no debarment of self or persons working on study
Sponsor: this is a key provision
FDACounsel.com 25
Record Retention Record Retention
Period of time various study records must be retained
21 CFR 312.57 (Sponsor’s duties) & 21 CFR 312.62 (Investigator’s duties) –
vague – could be two years, could be 15 years! ICH E6 5.5 (Global Studies)
Not incorporated into federal law in US (but required for global studies)
Retention until: 2 yrs after last approval of marketing app in an ICH
region and until no pending/contemplated apps -- or
2 yrs after discontinuation of investigational product.
FDACounsel.com 26
Record Retention … Problems
Long retention periods for site (as compared to site policies or fed law?)
Where to store records? Who pays?
Destruction of records Record retention policies may prohibit destruction Happy medium:
Require sponsor consent to destroy records; or Return records to sponsor (to extent allowable);
or Provide for indefinite retention at a third party
facility
FDACounsel.com 27
FDA Inspections Inspections
Right to notice FDA may inspect sponsor at “reasonable times” FDA may inspect Investigator at “reasonable
times” Sponsor’s right to be present during
FDA inspection of PI Replying to deficiencies Contrast this with “audit” right of
sponsor to inspect PI at “reasonable times”
FDACounsel.com 28
Termination What is it: ability to cancel
or “escape” performance of the contract without “breach”
Problems: Ability to terminate without cause (for
any reason) Assure this type of termination is in writing.
Duty to provide “reasonable notice” is required under modern case law; otherwise, contract may fail for lack of consideration.
FDACounsel.com 29
Termination … Sponsor: typically wants the right to
terminate w/out cause – Site incurs expenses upfront that are “amortized”
across the study (i.e. salary, supplies, advertising, patient recruitment) Happy Medium:
allow for appropriate remedies (see below) specify particular circumstances for termination, such
as:♦ FDA places a clinical hold♦ Safety issues♦ Investigator/site breaches
the agreement andbreach not cured w/in
time period.♦ Safe harbor: termination for
“business”decisions
FDACounsel.com 30
Termination … Site right to termination w/out cause
May be a duty to subjects to continue Termination of site can cause serious delays in getting
a particular drug to market (available to general public)
Happy medium -- specify circumstances Site may terminate:
PI unable to perform (leaves site) and acceptable replacement cannot be identified
FDA places a clinical hold or local IRB withdraws study approval
Sole discretion of PI, safety of subjects is compromisedSPONSOR – would want IRB concurrence to preclude arbitrary action
Sponsor materially breaches agreement and breach not cured w/in notice period
FDACounsel.com 31
Termination … Remedies
Problem: costs of termination (who bears the costs?)
Site perspective: Sponsor has the deep pockets and should bear all costs incurred by site for termination
Sponsor perspective: direct and consequential costs of a termination are extremely high (considering each day of delay in bringing a drug to market). Sponsor should not be responsible to Site for termination costs
Is there a happy medium?
FDACounsel.com 32
Termination … How about: Fixed-price (per patient) to
cost-reimbursement upon termination Per patient costs Non-cancelable obligations through date of
termination Unless: termination due to breach by Site,
then Fixed-price, per patient (pro-rated)
But, what if CRO involved? Gets a little dicier for the sponsor.
FDACounsel.com 33
Choice Of/Governing Law
Choice of/Governing law What is it?
Law: the state law that will be used in the event of dispute
Jurisdiction: The right and power of a particular court to adjudicate on a matter
Venue: where a dispute may be resolved
FDACounsel.com 34
Choice Of/Governing Law …
Problems: Customary that the “payer” dictates governing law:
PI obligations to patients make jurisdictional issues difficult
Site attorneys are familiar with own state law and jurisdiction (argument, if a dispute, parities typically hire outside counsel)
Happy medium♦ Remain silent (issue dealt with IF a dispute –
unlikely)♦ Chose law of state with a great deal of case law
(e.g., New York) or model corporate statutes (e.g., Delaware)
FDACounsel.com 35
Choice Of/Governing Law …
Problems … Many public sites cannot negotiate
law/jurisdiction as they are governed by state statute
Happy medium: Remain silent
FDACounsel.com 36
Assignment
What is it? Transfer by a party to a non-
party rights under a contract; or
Transfer of the rights and duties – assignment of the contract.
FDACounsel.com 37
Assignment … Problems
Sponsor right Due to industry climate, sponsor must have
the ability to assign its contracts (take-over, merger, etc.) without consent
Site must provide updates/possible administrative changes to the IRB, other administration considerations
Happy medium? Sponsor agrees to provide notice of
assignment: what is reasonable?
FDACounsel.com 38
Assignment … Sites/PI right
Site/PI picked because of reputation – becomes personal contract (which is not assignable)
Sponsor must have control over who is performing the trial (1572 form is required by the PI; what to do with subjects currently on protocol?; debarment or disqualification issues; quality issues)
May want to require sponsor consent to assign
assure that Site/PI must provide reasonable notice so that the protocol can be submitted and approved by the appropriate IRB; 1572 forms are completed and signed, a new CTA can be negotiated and signed
FDACounsel.com 39
Publicity
Publicity Sponsor and Site need control
over the use of their respective names
Problems may have federal (e.g., SEC) reporting
requirements Requirement to obtain written consent
for each use may be overly burdensome
FDACounsel.com 40
Publicity … Happy Medium:
Limit use to “promotional” purposes Sponsor – be careful here, though, that
there is not off-label, pre-approval promotion by site going on that could be attributed to you
Specify situations in which disclosure is okay Mandatory conflict of interest disclosures Federal/state/local reporting (sponsor and
amount of funding) Internal reporting requirements
FDACounsel.com 41
Order of Precedence In the event of a conflict between the terms of
the CTA and any attachments (protocol, budget, etc), what document controls?
1st view: terms of Protocol govern 2nd view: terms of Agreement govern
Problems: sometimes “contractual” terms are placed in
Protocol: confidentiality, publication. Other duplicate terms are in more than one
document: record retention, inspections, reporting requirements
Happy medium: Protocol governs scientific conduct of trial conduct of trial; Agreement governs all else
Caveat: be careful to define “scientific conduct” carefully and ensure that no key scientific duty is omitted from either document
FDACounsel.com 42
Authorized Representative
Similar issue to “Parties” Problem:
Ensure person signing has corporate authority
Include a representation that all necessary approvals to enter contract have been secured
FDACounsel.com 43
General Tips and Traps Know the parties
Commercial sponsor vs government Academia v independent lab or individual site
Important to recognize that the type of agreement you are looking at may not be titled correctly. Example: research v. services
Going Global? Take the Plunge. Hire outside counsel to
perform contract review: country/province specific laws governing clinical research and privacy.
Watch terminology – define with care – e.g., when is a clinical trial completed?
Write in plain English!!
FDACounsel.com 44
Questions?
Write, call, fax or e-mail:
Michael A. Swit, Esq.FDACounsel.com
THE LAW OFFICES OF MICHAEL A. SWIT539 Samuel Ct., Suite 229
Encinitas, CA 92024office: 760-815-4762 ♦ fax: 760-454-2979
FDACounsel.com 45
About your instructorMichael A. Swit has over 20 years of experience addressing critical FDA legal and regulatory issues. His vast and varied experience, which he is now providing as a solo practitioner, includes serving for three and a half years as vice president and general counsel of Pharmaceutical Resources, Inc. (PRI) a prominent generic drug manufacturer through its Par Pharmaceutical subsidiary. He thus also brings an industry and commercial perspective to his representation of FDA-regulated companies and, to that, effect also counsels on an array of transactional issues relating to FDA-regulated biomedical industry, including clinical research agreements, mergers & acquisitions, contract manufacturing, and due diligence inquiries.
While at PRI from 1990 to late 1993, Mr. Swit spearheaded the company’s defense of multiple grand jury investigations, other federal and state proceedings, and securities litigation stemming from the acts of prior management. Mr. Swit then served from 1994 to 1998 as CEO of Washington Business Information, Inc. (WBII) a premier publisher of FDA regulatory newsletters and other specialty information products for the FDA-regulated community. From May 2001 to May 2003, Mr. Swit was special counsel in the FDA Law Practice Group in the San Diego office of Heller Ehrman White & McAuliffe. Before that, he was twice in private practice with McKenna & Cuneo, from 1988 to 1990 and, most recently, from 1999 to 2001, first in that firm’s D.C. office and most recently, in its San Diego office. He first practiced FDA regulatory law with the D.C. office of Burditt & Radzius from 1984 to 1988.
Mr. Swit has taught and written on a wide variety of subjects relating to FDA law including, since 1989, co-directing a three-day intensive course on the generic drug approval process and editing a guide to the generic drug approval process, Getting Your Generic Drug Approved. He is a member of the California, Virginia and District of Columbia bars.
FDACounsel.com 46
Acknowledgements
The speaker gratefully acknowledges the help of Stacie Switzer, Esq., Corporate Counsel at Takeda Pharmaceuticals, and Nina Cannon, J.D. Manager, Contracts Management , at the Duke Clinical Research Institute/Duke University, whose recent presentation at the SRI Institute 14th Annual Clinical Trials Contracting Conference formed the basis for much of Part I of this presentation. Part II, in turn, is based on a joint presentation that I prepared with Ms. Switzer for the same conference.